Lung Cancer

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses subgroup analyses from the phase III PACIFIC trial in unresectable stage III non–small cell lung cancer (NSCLC).

Jessica Jiyeong Lin, MD, discusses rare oncogenic drivers and elaborates on the updated efficacy analyses that were presented at the 2019 ASCO Annual Meeting.

Alice T. Shaw, MD, PhD, provides an overlay of current treatment strategies in ALK-positive NSCLC and highlights research on the horizon.

Nicolas Girard, MD, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer who received durvalumab.